BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 33705876)

  • 1. Dry powder pharmaceutical biologics for inhalation therapy.
    Chang RYK; Chow MYT; Khanal D; Chen D; Chan HK
    Adv Drug Deliv Rev; 2021 May; 172():64-79. PubMed ID: 33705876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhalable microparticle platform based on a novel shell-forming lipid excipient and its feasibility for respirable delivery of biologics.
    Wang H; Connaughton P; Lachacz K; Carrigy N; Ordoubadi M; Lechuga-Ballesteros D; Vehring R
    Eur J Pharm Biopharm; 2022 Aug; 177():308-322. PubMed ID: 35905804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosing considerations for inhaled biologics.
    Ferrati S; Wu T; Kanapuram SR; Smyth HDC
    Int J Pharm; 2018 Oct; 549(1-2):58-66. PubMed ID: 30053488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability.
    Arora S; Haghi M; Young PM; Kappl M; Traini D; Jain S
    Expert Opin Drug Deliv; 2016; 13(2):183-93. PubMed ID: 26609733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
    Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
    Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amorphous powders for inhalation drug delivery.
    Chen L; Okuda T; Lu XY; Chan HK
    Adv Drug Deliv Rev; 2016 May; 100():102-15. PubMed ID: 26780404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spray Freeze Drying of Biologics: A Review and Applications for Inhalation Delivery.
    Farinha S; Sá JV; Lino PR; Galésio M; Pires J; Rodrigues MÂ; Henriques J
    Pharm Res; 2023 May; 40(5):1115-1140. PubMed ID: 36456666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, characterization, and aerosol dispersion performance modeling of advanced spray-dried microparticulate/nanoparticulate mannitol powders for targeted pulmonary delivery as dry powder inhalers.
    Li X; Vogt FG; Hayes D; Mansour HM
    J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):81-93. PubMed ID: 24502451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of excipients on the stability and aerosol performance of salmon calcitonin dry powder inhalers prepared via the spray freeze drying process.
    Poursina N; Vatanara A; Rouini MR; Gilani K; Najafabadi AR
    Acta Pharm; 2016 Jun; 66(2):207-18. PubMed ID: 27279064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of inhalable dry powder formulation of basic fibroblast growth factor.
    Ibrahim BM; Jun SW; Lee MY; Kang SH; Yeo Y
    Int J Pharm; 2010 Jan; 385(1-2):66-72. PubMed ID: 19853028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Formulation Factors on the Aerosol Performance and Stability of Lysozyme Powders: a Systematic Approach.
    Ferrati S; Wu T; Fuentes O; Brunaugh AD; Kanapuram SR; Smyth HDC
    AAPS PharmSciTech; 2018 Oct; 19(7):2755-2766. PubMed ID: 29488193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation of High-Performance Dry Powder Aerosols for Pulmonary Protein Delivery.
    Wilson EM; Luft JC; DeSimone JM
    Pharm Res; 2018 Aug; 35(10):195. PubMed ID: 30141117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Porous and highly dispersible voriconazole dry powders produced by spray freeze drying for pulmonary delivery with efficient lung deposition.
    Liao Q; Yip L; Chow MYT; Chow SF; Chan HK; Kwok PCL; Lam JKW
    Int J Pharm; 2019 Apr; 560():144-154. PubMed ID: 30731259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine as an excipient in spray dried powder for inhalation.
    Alhajj N; O'Reilly NJ; Cathcart H
    Drug Discov Today; 2021 Oct; 26(10):2384-2396. PubMed ID: 33872799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs.
    Miller DP; Tan T; Tarara TE; Nakamura J; Malcolmson RJ; Weers JG
    Mol Pharm; 2015 Aug; 12(8):2582-93. PubMed ID: 26052676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spray-Dried Inhalable Powder Formulations of Therapeutic Proteins and Peptides.
    Eedara BB; Alabsi W; Encinas-Basurto D; Polt R; Mansour HM
    AAPS PharmSciTech; 2021 Jun; 22(5):185. PubMed ID: 34143327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
    Vandenheuvel D; Singh A; Vandersteegen K; Klumpp J; Lavigne R; Van den Mooter G
    Eur J Pharm Biopharm; 2013 Aug; 84(3):578-82. PubMed ID: 23353012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of storage temperature on the stability of spray dried bacteriophage powders.
    Leung SSY; Parumasivam T; Nguyen A; Gengenbach T; Carter EA; Carrigy NB; Wang H; Vehring R; Finlay WH; Morales S; Britton WJ; Kutter E; Chan HK
    Eur J Pharm Biopharm; 2018 Jun; 127():213-222. PubMed ID: 29486303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein Aggregates in Inhaled Biologics: Challenges and Considerations.
    Ibrahim M; Wallace I; Ghazvini S; Manetz S; Cordoba-Rodriguez R; Patel SM
    J Pharm Sci; 2023 May; 112(5):1341-1344. PubMed ID: 36796636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient optimization of high-dose formulation of novel lyophilizates for dry powder inhalation by the combination of response surface methodology and time-of-flight measurement.
    Ohori R; Kiuchi S; Sugiyama S; Miyamoto K; Akita T; Yamashita C
    Int J Pharm; 2020 May; 581():119255. PubMed ID: 32217154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.